Pharmanovia is headquartered in Basildon

The life cycle management company, Pharmanovia, has appointed Nivedita Valentine as associate vice president of Product Innovation.

Ms Valentine will oversee the company’s product innovation operations and decision-making as Pharmanovia continues to focus efforts on both, identifying new prospects to enhance lifecycle management of its brands through incremental innovation. She will report to interim chief scientific officer Stephen Deacon and help bridge unmet patient needs with the help of novel therapies, originating both from in-house development and through partnerships.

Ms Valentine currently holds  positions on the value-added medicines committee within Medicines for Europe and the International Rare Diseases Research Consortium (IRDiRC) Task Force on Drug Repurposing Guidebook.

Pharmanovia CEO Dr James Burt commented: “Digitalization and utilizing the latest technological innovation are notable areas of acceleration within the pharma industry and Nivedita’s appointment will ensure iconic brands will continue to be improved, supported, and used sustainably.

“I am delighted to welcome Nivedita to Pharmanovia as we continue the next phase of our strategic growth journey.”

Backed by more than fifteen years of leadership experience, Ms Valentine brings deep market knowledge and technical expertise to Pharmanovia’s product innovation division. Previously she has held global senior management positions at Accord Healthcare and Glenmark Pharmaceuticals.

Commenting on her new role, Ms Valentine said: “Pharmanovia is at an incredibly exciting point within its growth journey, rapidly establishing its position as a leader in life cycle management with a strong, innovative pipeline.

“I’m excited to take on this role within such a committed, patient-centered organization with an incredibly talented, like-minded team who constantly seek to identify new ways to enhance the lives of the patients.”

 

If you want to share your stories and/or experiences with us, please send an email to editor@pharmacy.biz

LEAVE A REPLY